Skip to main content
SpringerLink
Log in

The Use of Oncolytic Herpesvirus for the Treatment of Cancer

  • Chapter
  • First Online:
Novel Technologies for Vaccine Development

  • 1174 Accesses

Abstract

Oncolytic immunotherapy is a new form of cancer treatment that utilizes native or genetically modified viruses to directly infect tumor cells. These viruses selectively replicate in tumor cells and may induce systemic antitumor immune responses. To date, the herpesviruses have been the most widely evaluated for clinical development as a cancer therapeutic. A modified herpesvirus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF) has been named talimogene laherparepvec (T-VEC) and has shown clinical benefits in a randomized Phase III clinical trial in patients with advanced melanoma. This chapter will review the basic mechanisms of oncolytic viruses, describe the basic biology of herpesviruses, and discuss the clinical results of trials with T-VEC. Future directions and priorities for clinical development of T-VEC and other oncolytic viruses will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Andtbacka RHI, Collichio F, Amatruda T et al (2013) OPTIM: a randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatement of unresectable stage IIIB/C and IV melanoma (abstract). Am Soc Clin Oncol Suppl; abstr LBA9008

    Google Scholar 

  • Carson WE (2005) Getting melanoma cells to stimulate with frequency. J Clin Oncol 23(35):8929–8931

    Article  PubMed  Google Scholar 

  • Disis ML, Bernhard H, Shiota FM et al (1996) Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88(1):202–210

    CAS  PubMed  Google Scholar 

  • Dranoff G, Jaffee E, Lazenby A et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90:3539–3543

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Filipazzi P, Valenti R, Huber V et al (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25(18):2546–2553

    Article  CAS  PubMed  Google Scholar 

  • Fong Y, Kim T, Bhargava A et al (2009) A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 17(2):389–394

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Geevarghese SK, Geller DA, de Haan HA et al (2010) Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 21(9):1119–1128

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Grotz TE, Kottschade L, Pavey ES, Markovic SN, Jakub JW (2014) Adjuvant GM-CSF improves survival in high-risk stage IIIc melanoma-a single-center study. Am J Clin Oncol 37(5):467–72

    Google Scholar 

  • Harrington KJ, Hingorani M, Tanay M et al (2010) Phase I/II study of oncolytic HSVGM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 16(15):4005–4015

    Article  CAS  PubMed  Google Scholar 

  • Harrow S, Papanastassiou V, Harland J et al (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11(22):1648–1658

    Article  CAS  PubMed  Google Scholar 

  • Hu JC, Coffin RS, Davis CJ et al (2006) A phase I study of OncoVexGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12(22):6737–6747

    Article  CAS  PubMed  Google Scholar 

  • Jinushi M, Nakazaki Y, Dougan M, Carrasco D, Mihm M, Dranoff G (2007) MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and anti-inflammatory activities of GM-CSF. J Clin Invest 117:1902–1913

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kaufman HL, Bines SD (2010) The OPTiM trial: a phase III prospective randomized clinical trial of an oncolytic herpesvirus encoding GM-CSF in patients with unresectable stage III or IV melanoma. Future Oncol 6(6):941–949

    Article  CAS  PubMed  Google Scholar 

  • Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17:718–730

    Article  PubMed  Google Scholar 

  • Kemeny N, Brown K, Covey A et al (2006) Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17(12):1214–1224

    Article  CAS  PubMed  Google Scholar 

  • Kimata H, Imai T, Kikumori T et al (2006) Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol 13(8):1078–1084

    Article  PubMed  Google Scholar 

  • Liu BL et al (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating and anti-tumour properties. Gene Ther 10:292–303

    Article  CAS  PubMed  Google Scholar 

  • Markert JM, Liechty PG, Wang W et al (2009) Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM. Mol Ther 17(1):199–207

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Papanastassiou V, Rampling R, Frasher M et al (2002) The potential for efficacy of the modified (ICP 34.5(−)) herpes simplex virus HSV 1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 9(6):398–406

    Article  CAS  PubMed  Google Scholar 

  • Pawlik TM, Nakamura H, Yoon SS et al (2000) Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 60(11):2790–2795

    CAS  PubMed  Google Scholar 

  • Rampling R, Cruickshank G, Papanastassio V et al (2007) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7(10):859–866

    Article  Google Scholar 

  • Senzer NN, Kaufman HL, Amatruda T et al (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27(34):5763–5771

    Article  CAS  PubMed  Google Scholar 

  • Serafini P, De Santo C, Marigo I et al (2004a) Derangement of immune response by myeloid suppressor cells. Cancer Immunol Immunother 53:64–82

    Article  CAS  PubMed  Google Scholar 

  • Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I (2004b) High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64:6337–6343

    Article  CAS  PubMed  Google Scholar 

  • Slingluff CL, Petroni GR, Yamshchikov GV et al (2003) Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21(21):4016–4026

    Article  CAS  PubMed  Google Scholar 

  • Slingluff CL, Petroni GR, Olson WC et al (2009) Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15:7036–7044

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Small EJ, Fratesi P, Reese DM et al (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18(23):3894–3903

    CAS  PubMed  Google Scholar 

  • Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24(19):3089–3094

    Article  CAS  PubMed  Google Scholar 

  • Spitler LE, Grossbard ML, Ernstoff MS et al (2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 18(8):1614–1621

    CAS  PubMed  Google Scholar 

  • Spitler LE, Weber RW, Allen RE et al (2009) Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II (T4), III, and IV melanoma. J Immunother 32(6):632–637

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 195 Little Albany Street, New Brunswick, NJ, 08901, USA

    Tasha Hughes

  2. Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, 08901, USA

    Howard L. Kaufman

Authors
  1. Tasha Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard L. Kaufman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard L. Kaufman .

Editor information

Editors and Affiliations

  1. Department of Pharmacology and Toxicolog Department of Microbiology and Immunolog, University of Louisville, Louisville, Kentucky, USA

    Igor S Lukashevich

  2. Department of Microbiology and Immunolog, University of Louisville, Louisville, Kentucky, USA

    Haval Shirwan

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Wien

About this chapter

Cite this chapter

Hughes, T., Kaufman, H.L. (2014). The Use of Oncolytic Herpesvirus for the Treatment of Cancer. In: Lukashevich, I., Shirwan, H. (eds) Novel Technologies for Vaccine Development. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1818-4_11

Download citation

Publish with us

Policies and ethics

Search

Navigation